Sanofi steps up with its data on a new MS drug, shining a spotlight on PhIII hopes after fending off a short attack

Sanofi CEO Paul Hudson was drawn early on in his new job to a multiple sclerosis drug in the pipeline, talking it up ahead of …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi steps up with its da­ta on a new MS drug, shin­ing a spot­light on PhI­II hopes af­ter fend­ing off a short at­tack